$55.67
3.26% yesterday
Nasdaq, Dec 24, 10:30 pm CET
ISIN
US92337R1014
Symbol
VERA

Vera Therapeutics Inc - Ordinary Shares - Class A Stock price

$55.67
+26.43 90.39% 1M
+33.09 146.55% 6M
+13.38 31.64% YTD
+13.75 32.80% 1Y
+35.77 179.75% 3Y
+44.17 384.09% 5Y
+44.17 384.09% 10Y
+54.97 7,852.86% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+1.76 3.26%
ISIN
US92337R1014
Symbol
VERA
Industry

Key metrics

Basic
Market capitalization
$3.9b
Enterprise Value
$3.5b
Net debt
positive
Cash
$497.4m
Shares outstanding
63.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
9.8
Financial Health
Equity Ratio
88.0%
Return on Equity
-26.4%
ROCE
-56.8%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-269.8m | $-303.4m
EBIT
$-270.2m | $-312.0m
Net Income
$-251.9m | $-297.9m
Free Cash Flow
$-211.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-85.8% | -81.6%
EBIT
-86.0% | -86.6%
Net Income
-87.5% | -95.8%
Free Cash Flow
-74.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.9
FCF per Share
$-3.3
Short interest
19.5%
Employees
192
Rev per Employee
$0.0
Show more

Is Vera Therapeutics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Vera Therapeutics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:

17x Buy
85%
3x Hold
15%

Analyst Opinions

20 Analysts have issued a Vera Therapeutics Inc - Ordinary Shares - Class A forecast:

Buy
85%
Hold
15%

Financial data from Vera Therapeutics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 81 81
155% 155%
-
- Research and Development Expense 189 189
67% 67%
-
-270 -270
86% 86%
-
- Depreciation and Amortization 0.39 0.39
680% 680%
-
EBIT (Operating Income) EBIT -270 -270
86% 86%
-
Net Profit -252 -252
87% 87%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vera Therapeutics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vera Therapeutics Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
16 days ago
BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of...
Neutral
GlobeNewsWire
17 days ago
BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of share...
Neutral
GlobeNewsWire
20 days ago
BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A c...
More Vera Therapeutics Inc - Ordinary Shares - Class A News

Company Profile

Vera Therapeutics, Inc. is a clinical stage biotechnical company that engages in the development and commercialization of transformative treatments for immunological diseases. Its primary product, atacicept, is a fusion protein self-administered as a subcutaneous injection that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in South San Francisco, CA.

Head office United States
CEO Marshall Fordyce
Employees 192
Founded 2016
Website veratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today